Skip to content

Clinical study on the application of extracorporeal shock wave in the treatment of early and middle stage knee osteoarthritis based on the meridian sinew theory

Clinical study on the application of extracorporeal shock wave in the treatment of early and middle stage knee osteoarthritis based on the meridian sinew theory

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100055064
Enrollment
Unknown
Registered
2021-12-31
Start date
2021-12-31
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

experimental group 1:Basic therapy + extracorporeal shock wave therapy
control group:Basic treatment + NSAIDs
experimental group 2:Basic therapy + extracorporeal shock wave therapy + point collection along the meridian

Sponsors

The Third Medical Center of the Chinese People's Liberation Army General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of western medicine and traditional Chinese medicine for knee osteoarthritis (KOA); 2. Aged 40-75 years; 3. Those who have not undergone systemic treatment recently and have not taken painkillers; 4. Subjects who mainly have traction pain on the back of the knee joint, with or without other syndromes of meridians and tendons, resulting in limited flexion and extension of joint function; 5. Subjects voluntarily participated in this study, signed the informed consent form, willing to cooperate with filling in relevant data, and accepting follow-up.

Exclusion criteria

Exclusion criteria: 1. X-ray imaging manifestations are Kellgren-Lawrence grade IV, with significantly narrowed joint space and subchondral bone sclerosis; 2. The knee joint has received arthroscopic surgery or open surgery in the past; 3. Patients with other rheumatic immune diseases, such as: rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, ankylosing spondylitis, etc.; 4. Patients with secondary knee OA, such as: acute and chronic knee infection, tumor, tuberculosis, blood, traumatic diseases; 5. Patients with severe deformity of the knee joint, knee varus >10 degree, knee valgus >20 degree and complete disappearance of the joint space are not suitable for conservative treatment; 6. Suffering from severe primary cardiovascular disease, lung disease, metabolic disease, endocrine disease and abnormal blood coagulation mechanism or other serious diseases that affect survival; 7. Received acetaminophen, cartilage nutrition drugs, joint cavity injection drugs and other related treatments in the past three months; 8. Those who cannot cooperate with MRI examination and have contraindications to MRI examination; 9. Those with contraindications to extracorporeal shock wave therapy; 10. Pregnant or lactating patients; 11. Suspect or do have a history of alcohol or drug abuse, or, according to the judgment of the investigator, have other diseases that reduce the possibility of enrollment or complicate enrollment, etc., which are likely to cause loss to follow-up; 12. Patients with serious adverse reactions and contraindications to the use of celecoxib capsules; 13. Other situations in which the researcher believes that the experiment cannot be successfully completed.

Design outcomes

Primary

MeasureTime frame
The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index;

Secondary

MeasureTime frame
Visual Analogue Scale;Gait analysis;MRI T2 mapping value;

Countries

China

Contacts

Public ContactXing Gengyan

The Third Medical Center of the Chinese People's Liberation Army General Hospital

1350138@163.com+86 13501384316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026